Acasti Total Liab vs Net Receivables Analysis

ACST Stock

USD 2.90 0.03 1.02%

Acasti Pharma financial indicator trend analysis is way more than just evaluating Acasti Pharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Acasti Pharma is a good investment. Please check the relationship between Acasti Pharma Total Liab and its Net Receivables accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Acasti Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

For more information on how to buy Acasti Stock please use our How to Invest in Acasti Pharma guide.

Total Liab vs Net Receivables

Total Liab vs Net Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Acasti Pharma Total Liab account and Net Receivables. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Acasti Pharma's Total Liab and Net Receivables is 0.9. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Acasti Pharma, assuming nothing else is changed. The correlation between historical values of Acasti Pharma's Total Liab and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Acasti Pharma are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Total Liab i.e., Acasti Pharma's Total Liab and Net Receivables go up and down completely randomly.

Correlation Coefficient

0.9

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Net Receivables

Most indicators from Acasti Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Acasti Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Acasti Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

For more information on how to buy Acasti Stock please use our How to Invest in Acasti Pharma guide.Selling General Administrative is likely to gain to about 9.8 M in 2024, despite the fact that Tax Provision is likely to grow to (8.2 M).

Acasti Pharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Other Liab	Net Tangible Assets	Accounts Payable	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Short Long Term Debt
Total Assets		0.05	0.03	0.98	-0.17	-0.75	-0.86	0.79	0.91	0.69	0.48	0.81	0.82	0.84	0.55	0.16	0.73	0.93	0.84	0.7	-0.42	-0.02	0.67	0.77	0.84	0.78
Other Current Liab	0.05		0.88	-0.09	0.46	-0.13	-0.29	0.08	-0.02	0.04	0.75	0.28	0.41	0.34	0.68	0.71	0.15	0.16	0.27	-0.11	0.42	-0.23	0.36	0.41	-0.15	0.49
Total Current Liabilities	0.03	0.88		-0.14	0.67	-0.11	-0.23	0.02	-0.01	0.09	0.81	0.24	0.43	0.31	0.8	0.8	0.13	0.1	0.29	-0.21	0.58	-0.11	0.41	0.41	-0.18	0.46
Total Stockholder Equity	0.98	-0.09	-0.14		-0.28	-0.73	-0.83	0.79	0.9	0.67	0.34	0.78	0.74	0.79	0.4	0.03	0.7	0.92	0.79	0.74	-0.54	-0.02	0.58	0.71	0.86	0.71
Property Plant And Equipment Net	-0.17	0.46	0.67	-0.28		0.03	-0.05	-0.16	-0.18	-0.16	0.49	0.05	0.23	0.16	0.45	0.72	-0.11	-0.06	0.03	-0.33	0.51	-0.44	0.05	0.12	-0.29	0.17
Net Debt	-0.75	-0.13	-0.11	-0.73	0.03		0.84	-0.97	-0.45	-0.92	-0.58	-0.83	-0.63	-0.8	-0.46	-0.2	-0.96	-0.79	-0.57	-0.92	0.65	0.03	-0.47	-0.8	-0.86	-0.83
Retained Earnings	-0.86	-0.29	-0.23	-0.83	-0.05	0.84		-0.84	-0.72	-0.69	-0.69	-0.96	-0.85	-0.97	-0.55	-0.45	-0.74	-0.96	-0.81	-0.74	0.48	0.26	-0.53	-0.92	-0.71	-0.94
Cash	0.79	0.08	0.02	0.79	-0.16	-0.97	-0.84		0.51	0.89	0.5	0.84	0.65	0.81	0.38	0.13	0.92	0.84	0.62	0.97	-0.72	-0.02	0.43	0.8	0.84	0.82
Non Current Assets Total	0.91	-0.02	-0.01	0.9	-0.18	-0.45	-0.72	0.51		0.43	0.36	0.69	0.76	0.72	0.47	0.19	0.42	0.82	0.86	0.41	-0.2	0.01	0.65	0.61	0.63	0.61
Cash And Short Term Investments	0.69	0.04	0.09	0.67	-0.16	-0.92	-0.69	0.89	0.43		0.5	0.71	0.49	0.63	0.47	0.03	0.96	0.65	0.54	0.85	-0.57	0.35	0.6	0.68	0.87	0.7
Net Receivables	0.48	0.75	0.81	0.34	0.49	-0.58	-0.69	0.5	0.36	0.5		0.63	0.77	0.72	0.9	0.79	0.56	0.56	0.66	0.28	0.17	-0.19	0.63	0.74	0.31	0.78
Common Stock Total Equity	0.81	0.28	0.24	0.78	0.05	-0.83	-0.96	0.84	0.69	0.71	0.63		0.78	0.96	0.52	0.48	0.72	0.93	0.78	0.73	-0.49	-0.15	0.51	0.91	0.69	0.94
Common Stock Shares Outstanding	0.82	0.41	0.43	0.74	0.23	-0.63	-0.85	0.65	0.76	0.49	0.77	0.78		0.89	0.7	0.55	0.54	0.87	0.92	0.49	-0.11	-0.29	0.61	0.81	0.47	0.85
Other Stockholder Equity	0.84	0.34	0.31	0.79	0.16	-0.8	-0.97	0.81	0.72	0.63	0.72	0.96	0.89		0.6	0.58	0.68	0.96	0.84	0.68	-0.38	-0.31	0.54	0.93	0.64	0.93
Total Liab	0.55	0.68	0.8	0.4	0.45	-0.46	-0.55	0.38	0.47	0.47	0.9	0.52	0.7	0.6		0.65	0.52	0.47	0.63	0.14	0.34	0.01	0.79	0.64	0.37	0.68
Property Plant And Equipment Gross	0.16	0.71	0.8	0.03	0.72	-0.2	-0.45	0.13	0.19	0.03	0.79	0.48	0.55	0.58	0.65		0.09	0.34	0.45	-0.09	0.39	-0.44	0.31	0.54	-0.11	0.53
Total Current Assets	0.73	0.15	0.13	0.7	-0.11	-0.96	-0.74	0.92	0.42	0.96	0.56	0.72	0.54	0.68	0.52	0.09		0.69	0.51	0.87	-0.57	0.15	0.56	0.72	0.89	0.76
Common Stock	0.93	0.16	0.1	0.92	-0.06	-0.79	-0.96	0.84	0.82	0.65	0.56	0.93	0.87	0.96	0.47	0.34	0.69		0.86	0.76	-0.51	-0.23	0.52	0.88	0.73	0.89
Other Liab	0.84	0.27	0.29	0.79	0.03	-0.57	-0.81	0.62	0.86	0.54	0.66	0.78	0.92	0.84	0.63	0.45	0.51	0.86		0.48	-0.14	-0.01	0.76	0.76	0.52	0.76
Net Tangible Assets	0.7	-0.11	-0.21	0.74	-0.33	-0.92	-0.74	0.97	0.41	0.85	0.28	0.73	0.49	0.68	0.14	-0.09	0.87	0.76	0.48		-0.86	0.02	0.27	0.66	0.83	0.68
Accounts Payable	-0.42	0.42	0.58	-0.54	0.51	0.65	0.48	-0.72	-0.2	-0.57	0.17	-0.49	-0.11	-0.38	0.34	0.39	-0.57	-0.51	-0.14	-0.86		0.01	0.12	-0.36	-0.63	-0.35
Short Term Investments	-0.02	-0.23	-0.11	-0.02	-0.44	0.03	0.26	-0.02	0.01	0.35	-0.19	-0.15	-0.29	-0.31	0.01	-0.44	0.15	-0.23	-0.01	0.02	0.01		0.39	-0.18	0.17	-0.18
Non Current Liabilities Total	0.67	0.36	0.41	0.58	0.05	-0.47	-0.53	0.43	0.65	0.6	0.63	0.51	0.61	0.54	0.79	0.31	0.56	0.52	0.76	0.27	0.12	0.39		0.53	0.56	0.56
Inventory	0.77	0.41	0.41	0.71	0.12	-0.8	-0.92	0.8	0.61	0.68	0.74	0.91	0.81	0.93	0.64	0.54	0.72	0.88	0.76	0.66	-0.36	-0.18	0.53		0.61	0.96
Other Current Assets	0.84	-0.15	-0.18	0.86	-0.29	-0.86	-0.71	0.84	0.63	0.87	0.31	0.69	0.47	0.64	0.37	-0.11	0.89	0.73	0.52	0.83	-0.63	0.17	0.56	0.61		0.62
Short Long Term Debt	0.78	0.49	0.46	0.71	0.17	-0.83	-0.94	0.82	0.61	0.7	0.78	0.94	0.85	0.93	0.68	0.53	0.76	0.89	0.76	0.68	-0.35	-0.18	0.56	0.96	0.62

Click cells to compare fundamentals

Acasti Pharma Account Relationship Matchups

Acasti Pharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	22.9M	62.5M	128.6M	79.1M	91.0M	95.5M
Other Current Liab	5.6M	1.4M	1.5M	3.3M	3.8M	2.7M
Total Current Liabilities	7.4M	1.6M	3.3M	3.4M	3.9M	3.7M
Total Stockholder Equity	13.0M	55.7M	108.3M	68.0M	78.1M	82.1M
Property Plant And Equipment Net	2.1M	86K	315K	567K	652.1K	654.3K
Net Debt	(14.1M)	(50.9M)	(30.0M)	(27.4M)	(24.7M)	(23.4M)
Retained Earnings	(126.3M)	(146.0M)	(155.8M)	(198.3M)	(178.4M)	(169.5M)
Cash	14.2M	50.9M	30.3M	27.9M	32.1M	33.7M
Non Current Assets Total	6.8M	86K	83.1M	49.8M	57.3M	60.2M
Cash And Short Term Investments	14.2M	60.7M	43.7M	27.9M	32.1M	19.2M
Net Receivables	546K	530K	548K	802K	721.8K	499.9K
Common Stock Shares Outstanding	1.8M	2.5M	6.1M	7.4M	8.6M	9.0M
Liabilities And Stockholders Equity	22.9M	62.5M	128.6M	79.1M	91.0M	95.5M
Other Stockholder Equity	9.8M	10.8M	12.2M	14.0M	16.1M	16.9M
Total Liab	9.9M	6.8M	20.4M	11.2M	12.8M	8.8M
Property Plant And Equipment Gross	2.1M	86K	315K	1.2M	1.4M	1.4M
Total Current Assets	16.1M	62.4M	45.5M	29.3M	33.7M	20.0M
Accumulated Other Comprehensive Income	(7.9M)	(6.3M)	(6.0M)	(6.0M)	(5.4M)	(5.2M)
Common Stock	137.4M	197.2M	258.0M	258.3M	297.0M	311.9M
Other Liab	12.2M	2.4M	5.2M	16.9M	19.4M	20.4M
Net Tangible Assets	4.7M	8.8M	55.7M	25.5M	29.3M	30.8M
Accounts Payable	1.7M	115K	1.7M	1.2M	1.4M	1.2M
Short Term Investments	5K	9.8M	13.3M	15K	13.5K	12.8K
Non Current Liabilities Total	2.5M	5.2M	17.1M	7.8M	8.9M	5.8M
Other Current Assets	195K	1.1M	1.3M	598K	687.7K	376.0K
Short Term Debt	76K	86K	104K	75K	86.3K	134.6K
Intangible Assets	5.8M	4.2M	69.8M	41.1M	47.3M	49.7M
Property Plant Equipment	2.1M	2.1M	86K	315K	362.3K	344.1K
Non Currrent Assets Other	429.8K	417.2K	473K	104K	93.6K	88.9K
Short Long Term Debt Total	147K	86K	295K	485K	557.8K	498.0K
Capital Lease Obligations	147K	86K	295K	485K	557.8K	585.6K
Net Invested Capital	13.0M	55.7M	108.3M	68.0M	78.1M	48.5M
Net Working Capital	8.7M	60.8M	42.3M	25.9M	29.8M	28.2M
Capital Stock	137.4M	197.2M	258.0M	258.3M	297.0M	208.5M

Pair Trading with Acasti Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acasti Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acasti Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with Acasti Stock

0.73	A	Agilent Technologies Financial Report 28th of May 2024	Pair Corr
0.74	ELEV	Elevation Oncology Earnings Call This Week	Pair Corr
0.84	FHTX	Foghorn TherapeuticsInc Financial Report 13th of May 2024	Pair Corr

Moving against Acasti Stock

0.61

MOLN

Molecular Partners Financial Report 10th of May 2024

Pair Corr

The ability to find closely correlated positions to Acasti Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acasti Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acasti Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acasti Pharma to buy it.

The correlation of Acasti Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acasti Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acasti Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Acasti Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Acasti Pharma is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Acasti Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Acasti Pharma Stock. Highlighted below are key reports to facilitate an investment decision about Acasti Pharma Stock:

How To Invest In Acasti

Details

Is Acasti Stock a good investment?

Details

What is Acasti Pharma's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Acasti Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

For more information on how to buy Acasti Stock please use our How to Invest in Acasti Pharma guide.

You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for Acasti Stock analysis

When running Acasti Pharma's price analysis, check to measure Acasti Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acasti Pharma is operating at the current time. Most of Acasti Pharma's value examination focuses on studying past and present price action to predict the probability of Acasti Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acasti Pharma's price. Additionally, you may evaluate how the addition of Acasti Pharma to your portfolios can decrease your overall portfolio volatility.

	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Volatility Analysis Get historical volatility and risk analysis based on latest market data
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio

Is Acasti Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Acasti Pharma. If investors know Acasti will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Acasti Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(5.68)

Revenue Per Share

0.005

Return On Assets

(0.08)

Return On Equity

(0.48)

The market value of Acasti Pharma is measured differently than its book value, which is the value of Acasti that is recorded on the company's balance sheet. Investors also form their own opinion of Acasti Pharma's value that differs from its market value or its book value, called intrinsic value, which is Acasti Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acasti Pharma's market value can be influenced by many factors that don't directly affect Acasti Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Acasti Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Acasti Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acasti Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Acasti Total Liab vs Net Receivables Analysis

Total Liab vs Net Receivables

Total Liab vs Net Receivables Correlation Analysis

Correlation Coefficient

Total Liab

Net Receivables

Acasti Pharma fundamental ratios Correlations

Acasti Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Acasti Pharma fundamental ratios Accounts

Pair Trading with Acasti Pharma

Moving together with Acasti Stock

Moving against Acasti Stock

Complementary Tools for Acasti Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 0.98	Total Assets
Net Tangible Assets	+ 0.97	Cash
Total Current Assets	+ 0.96	Cash And Short Term Investments
Other Stockholder Equity	+ 0.96	Common Stock Total Equity
Common Stock	+ 0.96	Other Stockholder Equity
Short Long Term Debt	+ 0.96	Inventory

Other Stockholder Equity	- 0.97	Retained Earnings
Cash	- 0.97	Net Debt
Common Stock	- 0.96	Retained Earnings
Common Stock Total Equity	- 0.96	Retained Earnings
Total Current Assets	- 0.96	Net Debt
Short Long Term Debt	- 0.94	Retained Earnings